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Introduction: 
Patients with cirrhosis have increased morbidity from hepatitis A (HAV) and B (HBV) 
infections, and vaccination against these infections is an important standard of care (1) (2). 
However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there 
is limited high quality literature available.  The aim of this work was therefore to compare 
immune responses of standard dose (SD) with high dose, accelerated (HDA) vaccination in 
cirrhotic patients.  
Patients and Methods: 
A single centre, prospective, non-randomized controlled trial, comparing SD versus HDA 
HAV and HBV regimens in consecutive patients with cirrhosis. 
The SD HAV schedule was intramuscular Twinrix® 720 µg at 0, 1 and 6 months. For 23% of 
patients the SD HAV schedule was intramuscular Havrix® 1440 µg at 0 and 6 months.  For 
patients failing to seroconvert, a single 1440 µg Havrix® booster was given. The HDA HAV 
schedule was Havrix® 1440 µg at 0, 1 and 2 months, with a single 720 µg booster for 
patients failing to seroconvert. 
The SD HBV schedule was intramuscular Twinrix® or Engerix®-B 20 µg at 0, 1 and 6 
months with a 40 µg booster of Engerix®-B if non-immune. The HDA HBV schedule was 
Twinrix® or Engerix®-B 40 µg at 0, 1 and 2 months, with the schedule repeated as a booster 
if non-immune. The combined vaccine Twinrix® was used for initial vaccination in 48% of 
patients. 
The HDA regimens were designed following review of literature and to provide 
approximately double the SD in one third of the time.  The SD (HAV and HBV) cohort study 
occurred during the time period of 2009-2011. The HDA cohort study occurred during a 
separate time period during 2012-2014. 
For multivariate models those variables significant at p<0.20 were considered for inclusion in 
the model. 
Results: 
In the HAV arm, 73 and 35 patients received SD and HDA schedules, respectively. In the 
HBV vaccination arm, 97 and 51 patients received the SD and HDA regimens, respectively. 
Groups were well matched for important clinical characteristics. The percentage of patients 
with decompensated (Childs-Pugh B/C) disease in the HAV and HBV study arms was 38% 
and 43%, respectively. 18 patients did not adhere to boosting protocols and were excluded 
from relevant per protocol analyses. 
In the HAV arm, initial response rates were 79.5% (58/73) in the SD arm and 94.3% (33/35) 
in the HDA arm (p=0.065). Boosting regimens were successful in 66.7% (8/12) in the SD 
arm and 100% (1/1) in the HDA arm. Per protocol immune response rates for the SD HAV 
vaccination arm was 94.3% (66/70) and 100% (34/34) in the HDA arm (p=0.16). 
In the HBV arm, the initial response rates were 51.5% (50/97) in the SD arm and 45.1% 
(23/51) in the HDA arm (p=0.49). Boosting regimens were successful in 28.6% (12/42) in the 
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SD group and 52.6% (10/19) in the HDA arm (p=0.07). Per protocol immune response rates 
was 67.4% (62/92) in the SD arm and 78.6% (33/42) in the HDA arm (p=0.19). 
Only one factor across both HAV and HBV studies, low albumin in the HBV SD arm, was 
significantly associated with immune non-response on multivariate analysis (Tables 1A and 
1B). 
There were no vaccination-related serious adverse events seen in any patients. 
 
Discussion: 
Results from this study suggest a potential benefit from an initial HDA HAV regimen in all 
cirrhotic patients. Benefits of this approach include: a clinically significant 15% improved 
immune response, rapid immune response, and minimal increased cost. 
Results do not support the routine use of the initial HDA HBV vaccination regimen in 
cirrhotic patients, but do suggest a potential benefit from HDA boosting of initial non-
responders. The HDA boosting regimen was associated with a clinically significant 23% 
improved response rate. 
Neither HAV nor HBV immune non-response were associated with MELD or Child-Pugh 
score or older age, as suggested by some authors (3-5) (6, 7).  The association of low albumin 
(a possible surrogate for advanced liver disease) with non-response to SD HBV vaccine, 
suggests that HDA boosting regime may have greatest utility in these patients. 
The non-randomized study design and lack of statistical power are weaknesses of our study, 
which limited our ability to draw firm conclusions. Post-hoc power analysis suggested that 76 
patients (HAV) and 120 patients (HBV) per group were required for the trends seen in initial 
HDA HAV and secondary HDA HBV immune responses to achieve statistical significance. 
Nevertheless, it should be noted that there are no randomized studies in this field and our 
study is one of the largest vaccination studies in cirrhotic patients to date. A further strength 
was the selection of a cirrhotic population with a range of disease severity and aetiology, 
enabling improved external generalizability of findings to cirrhotic patients seen typically in 
hepatology services. 
In conclusion, we believe the study findings provide the rationale for future randomized, 
adequately powered studies investigating benefits of an initial HAV HDA regimen and a 
secondary HBV HDA boosting regimen in cirrhotic patients. 
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ACCEPTED MANUSCRIPTTable 1A. Univariate and multivariate logistic regression for Hepatitis A vaccination 
response using per protocol analysis 
 Univariate 
(n=108) 
  Multivariate1 
(n=108)  
 
 Odds ratio (95 CI) p-value  Odds ratio (95 CI) p-value 
Age 0.96 (0.86, 1.06) 0.407  0.95 (0.84, 1.06) 0. 329 
Gender (M vs F) 1.76 (0.18, 17.56) 0.629  2.37 (0. 18, 131.8) 0.848 
Child score 1.18 (0.63, 2.22) 0.608    
Smoker 1.70 (0.16, 17.65) 0.657    
Drinker 1.16 (0.12, 11.61) 0.901    
High vs Low dose 2.65 (0.32, ∞) 0.400  3.10 (0.37, ∞) 0.326 
Total dose (µg) 
Albumin 
0.999 (0.998, 1.000) 
1.04 (0.89, 1.22) 
0.344 
0.600 
   
INR 1.81 (0.03, 96.9) 0.769    
Bilirubin 1.00 (0.96, 1.05) 0.771    
Creatinine 0.999 (0.976, 1.023) 0.968    
Meld score 1.057 (0.81, 1.38) 0.685    
Combined vaccine 0.35 (0.03, 3.45) 0.366    
Etiology 
   HCV 
   ETOH 
   HCV and ETOH 
   NASH 
 
1.00 
2.61 (0.15, 44.01) 
0.83 (0.05, 14.48) 
0.72 (0.04, 12.64) 
 
- 
0.505 
0.900 
0.824 
   
1Included high versus low dose and age and gender.  
 
Table 1B. Univariate and multivariate logistic regression for hepatitis B vaccination 
response using per protocol analysis 
 Univariate 
(n=134) 
  Multivariate1 
(n=134)  
 
 β (95 CI) p-value  β (95 CI) p-value 
Age 0.959 (0.926, 0.994) 0.021  0.96 (0.93, 1.00) 0.053 
Gender (M vs F) 0.57 (0.25, 1.30)  0.178  0.55 (0.23, 1.33) 0.184 
Child score 0.95 (0.79, 1.16) 0.63    
Smoker 1.53 (0.52, 4.44) 0.44    
Drinker 1.32 (0.61, 2,88) 0.48    
High vs Low dose (@albumin=34.5) 1.77 (0.75, 4.18) 0.189  1.98 (0.77, 5.13) 0.157 
Total dose (µg) 
Albumin  
   Low dose arm 
   High dose arm 
0.991 (0.985, 0.997) 
 
1.12 (1.03, 1.21) 
0.92 (0.82. 1.04) 
0.005 
 
0.008 
0.185 
  
 
1.12 (1.03, 1.21) 
0.94 (0.82, 1.07) 
 
 
0.008 
0.323 
INR 1.53 (0.39, 6.04) 0.55    
Bilirubin 1.00 (0.99, 1.01) 0.82    
Creatinine 0.992 (0.978, 1.007) 0.311    
Meld score 1.03 (0.94, 1.12) 0.50    
Renal disease 0.817 (0.072, 9.282)  0.871    
Etiology 
   HCV 
   ETOH 
   HCV and ETOH 
   NASH 
   Other 
 
1.00 
1.13 (0.32, 3.97) 
1.00 (0.19, 5.15) 
0.72 (0.15, 3.54) 
0.70 (0.13, 3.79) 
 
- 
0.856 
1.000 
0.686 
0.679 
   
1Included high versus low dose, albumin and age and gender and an interaction term for albumin X 
dose.  
